The CMV promoter drives high transgene expression and is one of the most commonly used promoters for gene transfer. Tissue-specific mammalian promoters provide an alternative, and it would be useful to have a system to directly compare them to viral promoters free from potential confounding vector-related effects. In this study, we describe how electroporation after subretinal injection of plasmid DNA can be used to perform comparative quantitative analysis of promoter activities. Luciferase assay of eyecup homogenates was carried out after coinjection/electroporation of pGL2, a plasmid containing the promoter fragment of interest coupled to the firefly luciferase gene, and pRL-CMV, a plasmid containing the CMV promoter coupled to the Renilla luciferase gene for normalization. This technique was used to compare activity of different fragments of the 5 0 -upstream region of the vitelliform macular dystrophy 2 ( VMD2) gene, which is selectively expressed in the retinal pigmented epithelial (RPE) cells, and results indicated positive regulatory elements between À104 and À154 bp and between À424 and À585 bp. Addition of a fragment from intron 1 reduced the activity of the À585/+38 bp fragment by 75%. Deletion analysis implicated a 342 bp region near the 5 0 -end of intron 1 in the repression. Results of transient transfections in two cell lines that constitutively express VMD2 were similar, and results in transgenic mice were consistent, providing validation for promoter analysis by in vivo electroporation. We then explored the time course of expression of the À585/+38 VMD2 promoter fragment and found that compared to cassettes driven by CMV or SV40 promoters, which showed peak luciferase activity on day 2 followed by a rapid decrease in activity, the VMD2 promoter fragment showed lower activity initially, but the activity was sustained for up to 56 days (longest time point measured). A promoter fragment from another RPE-specific gene, Rpe65, showed a similar pattern of sustained expression for at least 112 days. These data indicate that nonviral gene transfer can be used to quantitatively evaluate the activity of promoter fragments independent of influence from viral vectors. A potentially important finding using this new technique is the demonstration that relatively sustained passenger gene expression can be achieved with nonviral gene transfer using mammalian rather than viral promoters. Gene Therapy (2006) 13, 798-804.
Introduction
Development and differentiation of tissues depend upon altered patterns of gene expression, and in order to understand these complex processes it is necessary to understand the mechanisms by which altered gene expression occurs. Disease states are often associated with increased or reduced expression of critical gene products; therefore, the ability to modulate gene expression can provide the basis for therapies. Thus, identifying promoter regions of genes and determining how they interact with other regions of DNA and transcription factors to control gene expression is an important area of study.
The CMV promoter has often been used for gene transfer, because it drives high transgene expression initially. There may be advantages to utilizing tissuespecific mammalian promoters, but to determine this requires finding DNA fragments with optimal activity by identifying positive regulatory regions and excluding negative regulatory regions, and then determining how the activity of optimized fragments compared to that of the CMV promoter with regard to level and duration of transgene expression.
A common strategy used to identify regulatory regions of DNA for a particular gene and study their activities is to isolate fragments of the 5 0 -upstream region of the gene, couple them to a reporter gene, introduce them into cultured cells by transient transfection, and quantitatively compare reporter gene expression resulting from the various fragments. Since regulatory activities of DNA fragments are often dependent upon the presence and levels of transcription factors, the ideal cultured cells for such studies should express all relevant transcription factors at the same levels as the cells of interest in vivo. This is often a problem for highly differentiated, post-mitotic tissues, because cultured cells from such tissues tend to de-differentiate. For instance, proliferating cultured retinal pigmented epithelial (RPE) cells fail to express many critical proteins seen in RPE cells in vivo, and although manipulation of culture conditions can help, the cells still do not reflect many important aspects of their cells of origin. 1 Another approach that eliminates artefacts inherent in the use of cultured cells is to use the various fragments of the 5 0 -upstream region coupled to a reporter gene to generate transgenic mice. This approach involves considerably more time and expense but has essentially become the gold standard by which the temporal and spatial specificity of promoter fragments is confirmed. However, there is a significant problem in addition to the long duration and high expense of studies utilizing transgenic mice. The site of integration of a transgene into the genome can strongly influence its activity, so unless multiple independent lines show similar results, firm conclusions cannot be made.
We have recently shown that electroporation after subretinal injection of a plasmid containing an expression construct results in efficient expression of the passenger gene in RPE cells. 2 This technique provides a means for in vivo transfection free from the influence of viral vectors. In this study, we have explored the utility of this technique for analyzing the activity of 5 0 -upstream fragments of the VMD2 gene, a gene that is selectively expressed in RPE cells and which we have also studied using conventional techniques. 3 After validation of the technique, we compared the time course of expression achieved using a promoter fragment of VMD2 and another mammalian promoter, the Rpe65 promoter, with the time course of expression achieved with two viral promoters.
Results

Identification of positive regulatory elements in the VMD2 promoter by in vivo electroporation
Initial experiments were carried out to identify appropriate amounts of pGL2 and pRL-CMV for coinjection. Electroporation after subretinal injection of 0.5 mg of pGL2 containing the À585/+38 VMD2 promoter fragment and various amounts of pRL-CMV resulted in strong positive correlations between firefly and Renilla luciferase activities when 1 ng or less of pRL-CMV was injected (data not shown). However, for injections of 2 ng or more of pRL-CMV, there was a negative correlation between firefly and Renilla luciferase activities, suggesting that CMV promoter activity above a critical threshold inhibited VMD2 promoter activity; therefore, 0.25 ng of pRL-CMV was used for subsequent experiments.
After in vivo electroporation of pRL-CMV and pGL2 containing the various VMD2 promoter fragments, relative normalized luciferase values were 905, 449, 405, 378, 396, and 32 for À585/+38, À424/+38, À253/+38, À204/+38, À154/+38, and À104/+38, respectively (Figure 2) . Deletion of the regions between À585 and À424 bp or between À154 and À104 bp resulted in significant reductions in promoter activity, suggesting the presence of positive regulatory elements in these regions.
Transgenic mice generated with VMD2 fragments containing intron 1
In our previous transgenic mouse studies, 3 two of three independent lines of transgenic mice, generated with the À2948/+38 VMD2 promoter fragment coupled to LacZ, showed LacZ expression in RPE cells, and two of five independent lines obtained with the À585/+38 fragment showed expression in RPE cells. In this study, we generated transgenic mice with the À2948/E2 fragment containing intron 1 (Figure 1 ). There was no identifiable expression of LacZ in RPE cells in three independent lines. This suggests the possibility that negative regulatory elements are present in intron 1, but also highlights one of the major limitations of the transgenic approach. Since integration site can have a major influence on transgene expression, a negative result must be viewed with caution, particularly when only three transgenic lines are obtained.
Identification of a negative regulatory region in intron 1 of VMD2 by in vivo electroporation Several constructs were generated that incorporated intron 1 and extended 17 bp into exon 2 (designated E2 constructs, Figure 1 ) for comparison with similar fragments that extended only to 38 bp into exon 1. Relative luciferase activities after in vivo electroporation of pRL-CMV and pGL2 containing À2948/+38, À2948/ E2, À585/+38, or À2948/E2 were 915, 342, 905, and 217, respectively (Figure 3a) . Thus, addition of intron 1 to the À2948/+38 or À585/+38 fragments resulted in reductions in activity of 63 and 76%, respectively, suggesting the presence of negative regulatory elements in intron 1.
To identify the region of intron 1 responsible for this repression, three deletion constructs were generated ( Figure 1 ). Deletion of 336 bp in the middle of intron 1 (deletion 2) or 392 bp near the 3 0 -end of intron 1 (deletion 3) resulted in little change in activity compared to the constructs containing intact intron 1 (Figure 2a) . However, deletion of 342 bp near the 5 0 -end of intron 1 (deletion 1) resulted in a relative luciferase activity that was significantly higher than that seen with the construct that contained intact intron 1 and not significantly different from the activity of the À585/+38 construct Figure 1 The human VMD2 promoter and intron 1. Four constructs were generated from a 3.5 kb 5 0 -upstream genomic fragment of the VMD2 gene by digestion with BspHI/XcmI for À2948 to +38 bp, BspHI/PstI for À2948 to +17 bp of exon 2), EcoRI/ XcmI for À585 to +38 bp, and EcoRI/XcmI for À585 to +17 bp of exon 2). The latter fragment was used to generate the three deletion constructs as described in Materials and methods. 
Confirmation of a negative regulatory element in intron 1 of the VMD2 gene by transient transfections in cultured cells
VMD2 is expressed at a moderate level in the human neuroepithelioma cell line, SK-N-MC, 4 and at a lower level in the D407 RPE cell line, 5 and we have previously used these cell lines for VMD2 promoter analysis. 3 In SK-N-MC cells, transient cotransfection of pRL-CMV and pGL2 containing À2948/E2 or À585/E2 resulted in significantly less normalized luciferase activity than that seen after cotransfection of pRL-CMV with pGL2 containing À2948/+38 or À585/+38, respectively ( Figure  3b ), corroborating the finding from the in vivo electroporation studies that there are negative regulatory elements in intron 1. The deletion 1 construct had significant recovery of activity compared to the À585/ E2 construct, although it was not the complete recovery seen with in vivo electroporation ( Figure 3b ). This supports the presence of repressor elements in the 5 0 region of intron 1.
Overall, the findings with RPE in vivo and SK-N-MC cells were more similar to each other than to the findings with D407 cells. While both the À2948/+38 and À585/ +38 constructs showed relatively high activity in RPE in vivo and SK-N-MC cells, the À2948/+38 construct showed significantly less activity than the À585/+38 construct in D407 cells (Figure 3c ). Therefore, it is not surprising that addition of intron 1 to the À2948/+38 construct had no significant effect in D407 cells. However, the presence of negative regulatory elements in intron 1 was also suggested in D407 cells, because addition of intron 1 to the À585/+38 construct caused a dramatic reduction in activity that was statistically significant. In both, SK-N-MC and D407 cells, deletion 1 resulted in significant reduction of repression, although the recovery by deletion 1 was less clear in D407 cells, because deletion 2 also caused some recovery. Figure 3 Identification of negative regulatory elements in intron 1 of VMD2 by in vivo electroporation. Transfections were carried out for RPE in vivo (a) by subretinal injection and electroporation or by in vitro transfection for SK-N-MC cells (b) or D407 cells (c) using the constructs listed along the X-axis. Each bar represents the mean (7s.e.m.) ratio of normalized luciferase activity (calculated as described in the legend to Figure 2 ) of the listed VMD2 promoter fragment to that of empty pGL2 vector. Note that in RPE cells in vivo and both cell lines, the À2948/+38 and À585/+38 constructs had the highest promoter activities and they were reduced by addition of intron 1. Having demonstrated that in vivo electroporation provides a useful way to quantify promoter activity, we sought to compare the time course of expression of the À585/+38 VMD2 promoter fragment with the time course of expression of the CMV promoter. After coinjection/electroporation of 0.5 mg of pGL2 containing À585/+38 with 0.25 ng of pRL-CMV, the Renilla luciferase activity driven by the CMV promoter peaked 2 days after electroporation and declined rapidly so that compared to the peak, activity had dropped to 50% by day 3, 4% by day 7, and less than 1% on days 14 and 56 (Figure 4a ). The firefly luciferase activity driven by the VMD2 promoter gradually increased and then was sustained at or near its peak level at all subsequent time points out to 56 days, the last time point examined (Figure 4b ). Coinjection/electroporation of 0.5 mg of pGL2 containing À585/+38 with 0.25 ng of pRL-SV40 showed that the time course of Renilla luciferase expression driven by the SV40 promoter had an early peak and rapid decline (Figure 4c ) similar to that seen with the CMV promoter. To determine if prolonged expression was unique to the VMD2 promoter, or whether it was a feature shared by other mammalian promoters, the time course of expression of the Rpe65 promoter, another promoter selectively expressed in RPE cells, was examined. After coinjection/electroporation of 0.5 mg of pGL2 containing the Rpe65 promoter with 0.25 ng of pRL-CMV, the firefly luciferase activity driven by the Rpe65 promoter gradually increased and then was sustained at or near its peak level at all subsequent time points out to 112 days, the last time point examined (Figure 4d ).
Discussion
We previously demonstrated that subretinal injection of plasmids containing expression constructs followed by electroporation results in efficient transduction of RPE cells. 2 In this study, we investigated whether this technique could be adapted to perform quantitative analysis of promoter fragments by cotransduction of fragments of interest with another promoter fragment for normalization. In vivo electroporation of 5 0 -upstream regions of the VMD2 gene ranging from À2948/+38 to À104/+38 suggested that maximal activity is retained by the À585/+38 fragment and that there is a substantial reduction in activity when the region between À585 and À424 bp is deleted, which agrees with findings obtained by transient transfections in two cell lines that express VMD2 and findings in transgenic mice.
3 This is also consistent with electromobility supershift assay results indicating that RPE nuclear extracts contain binding activities to the À585 to À540 bp region. Other positive regulatory elements were identified between À154 and À104 bp. Negative regulatory elements were identified in intron 1 using in vivo electroporation consistent with the However, the similarities are greater than the differences, and these agreements between the traditional techniques used for promoter analysis and in vivo electroporation provide validation for the latter, and suggest that it will be valuable for future studies aimed at identification and characterization of regulatory elements in the promoters of genes that are expressed in native RPE cells. The in vivo electroporation technique allows for assessment of the expression of reporter constructs in RPE cells in vivo, which is also achieved by generating transgenic mice that express the construct, but compared to the transgenic approach, it is much faster, less expensive, and does not suffer from influence from integration site. A disadvantage of the in vivo electroporation technique is that subretinal injections in mice are technically challenging.
Having validated in vivo electroporation as a reliable technique for quantitative promoter analysis, we used it to compare the expression profiles of two mammalian promoters that are active in RPE cells, VMD2 and Rpe65, with those of two viral promoters, CMV and SV40. While the viral promoters expressed at very high levels initially, their expression levels rapidly declined. This is not related to the reporter genes used, because a previous study using a LacZ reporter gene also demonstrated rapid reduction in CMV promoter-mediated expression after in vivo electroporation. 2 In contrast, the VMD2 and Rpe65 promoters gradually increased to a plateau and maintained that level for at least 56 days. Previous studies using viral promoters have suggested that transient expression is a major limitation for developing therapies based on nonviral gene transfer, 2 but the present study suggests that this problem may be reduced or eliminated by using mammalian promoters.
Subretinal injection of adenoviral vectors containing expression constructs utilizing a CMV promoter results in efficient transfection of RPE cells and strong expression of passenger genes that peaks within a few days and becomes undetectable by 1 month after injection. 6, 7 Transient transgene expression also occurs after intramuscular administration of adenoviral vectors. [8] [9] [10] Since duration of expression is increased in immunocompromised mice or by immunosuppression, it has been assumed that elimination of viral genomes by the immune system is responsible for the reduction in expression. 7, 9, 10 However, comparison of vector DNA and transgene mRNA levels at several time points after intramuscular injection of an adenoviral vector, containing an expression construct utilizing a CMV promoter, demonstrated that mRNA decreased much more rapidly than vector DNA. 11 Extensive methylation of the CMV promoter was noted, suggesting the possibility that methylation-induced silencing of transcription plays a role in the transient expression observed with adenoviral vectors utilizing a CMV promoter. However, there are other possible contributors to transcriptional silencing after injection of adenoviral vectors including cytokineinduced suppression 12 and histone deacetylation. 13 While additional work is needed to clearly establish the mechanism of the transcriptional silencing, it has recently been demonstrated that it is partially reversible. The CMV promoter has several retinoic acid response elements and its activity is stimulated by all-trans retinoic acid (tRA).
14 After in vitro or in vivo transfection with adenoviral vectors utilizing a CMV promoter, treatment with tRA increases transgene expression. 15 In mouse eyes in which expression of luciferase had declined after intravitreous injection of an adenoviral vector containing a luciferase reporter gene driven by a CMV promoter, reactivation of expression occurred after systemic administration of tRA. 16 If transcriptional silencing of the CMV promoter plays a substantial role in the transient expression profile experienced in many studies investigating adenoviralmediated gene transfer, then use of other promoters should be tested. There are many studies that suggest that there are advantages to using tissue-specific mammalian promoters in adenoviral vectors, [17] [18] [19] [20] but the issue of whether transcriptional silencing occurs with mammalian promoters and if so how it compares to silencing of the CMV promoter has not been well studied. If the results of the present study, in which we found sustained expression after nonviral gene transfer with mammalian tissue-specific promoters, can be generalized to adenoviral gene transfer, the prospects for therapeutic use of adenoviral vectors could be greatly improved. Additional studies are needed to explore this possibility.
Materials and methods
Mice BALB/cJ (Jackson Laboratory, Bar Harbor, ME, USA) and transgenic mice were treated humanely in strict compliance with the Association for Research in Vision and Ophthalmology statement on the use of animals in research.
Plasmid construction
Plasmids containing upstream fragments of VMD2 ( Figure 1 ) were constructed as previously described. 3 Four genomic DNA fragments were generated by digestion with BspHI/XcmI for À2948 to +38 bp (À2948/+38), BspHI/PstI for À2948 to 17 bp in exon 2 (À2948/E2), EcoRI/XcmI for À585 to +38 bp (À585/+38), and EcoRI/XcmI for À585 to 17 bp in exon 2 (À585/E2). Three fragments for deletion constructs were generated by excluding 300-400 bp near the 5 0 -end, middle, or near the 3 0 -end of intron 1 from À585/E2 using the following restriction enzyme sets: BsaBI/AgeI for deletion of 342 bp near the 5 0 -end of intron 1 (À585/E2, deletion 1); AgeI/AccI for deletion of 336 bp in the middle of intron 1 (À585/E2, deletion 2); AccI/BbsI for deletion of 392 bp near the 3 0 -end of intron 1 (À585/E2, deletion 3) (Figure 1 ). Five shorter fragments were generated by PCR and confirmed by sequencing: À424 to +38 bp (À424/+38), À253 to +38 bp (À253/+38), À204 to +38 bp (À204/+38), À154 to +38 bp (À154/+38), and À104 to +38 bp ( 104/+38). One fragment (À2948/E2) was blunt end ligated into the SmaI site upstream of lacZ gene in placF vector (kindly provided by Dr Jacques Peschon, Immunex Corp., Seattle, WA, USA) for transgenic mouse studies. All fragments were blunt end ligated into the SmaI site of the pGL2-Basic vector containing the 21 was generated by PCR using the forward primer, 5 0 -CAT TCT TTC CAT AGC CCA CA-3 0 and the reverse primer, 5 0 -GGT CTG GCG ACT AGG CTG GT-3 0 . The correct sequence was confirmed and then the fragment was digested with XhoI and HindIII, and ligated into pGL2-Basic vector.
Generation of transgenic mice
Transgenic mice were generated using four different VMD2 promoter fragments coupled to the LacZ reporter gene as part of a previous study. 3 In the present study, the À2948/ E2 fragment driving lacZ was used to generate transgenic mice by microinjection into mouse one-cell embryos (B6/ SJL F2 hybrid) in the Transgenic Mouse Core Facility of the Johns Hopkins University School of Medicine. Mouse pups were screened to determine positive transgenic founders by both Southern blot analysis and PCR of tail DNA. Primers for PCR were: forward, 5 0 -ACA TCA GCC GCT ACA GTC AA-3 0 and reverse, 5 0 -GCG AGA TGC TCT TGA AGT CT-3 0 . Transgenic founders were crossed with wild-type BALB/cJ mice to generate progeny in an albino background, which facilitates identification of LacZ staining in RPE cells.
Assessment of LacZ staining in transgenic mice
Mice were killed and eyes were fixed in 2% paraformaldehyde and 0.25% glutaraldehyde for 1 h at 41C for sectioning or 0.5% glutaraldehyde for RPE/choroidal flat mounts. For sectioning, eyes were cryoprotected in 25% sucrose in PBS at 41C for 12-18 h, mounted in optimum cutting temperature embedding compound (OCT; Miles Diagnostics, Elkhart, IN, USA). Sections were stained with 1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal), 5 mM K 3 Fe(CN) 6 , 5mM K 4 Fe(CN)6 . 3H 2 O, 1 mM MgCl 2 in PBS at 371C for 16-24 h. For RPE/choroidal flat mounts, whole fixed eyes were stained in X-gal solution at 371C for 16-24 h, the anterior segment and retina were removed, radial cuts were made in the eye cup and it was mounted in Aquamount with the sclera facing down.
Cell cultures and transient transfections
The D407 RPE cell line 5 and the SK-N-MC neuroepithelioma cell line 4 were grown as previously described. Cells were transfected 40-48 h after plating at 70-80% confluence using 9 mg of a firefly luciferase construct and 1 mg of pCMV-lacZ using LipofectAMINE PLUS reagent (Invitrogen). Six independent tranfections were carried out in duplicate. Cell lysates were prepared 48-60 h after transfection using 300 ml of Reporter Lysis Buffer (Promega). Luciferase and b-galactosidase activities were measured as previously described. 3 Statistical analysis was performed using ANOVA and Tukey-Kramer test setting a-level to 0.05.
In vivo transfection of RPE cells
In vivo transfection of RPE cells was performed using 6-to 8-week-old BALB/cJ mice as previously described. 2 Briefly, the mice were given a subretinal injection of 1 ml of PBS containing 0.5 mg of pGL2 containing a firefly luciferase construct in which the test promoter fragment was used and 0.25 ng of Renilla luciferase plasmid (pRL-CMV, Promega) for normalization. After injection, two steel electrodes separated by about 3.0 mm were placed on the posterior sclera and an ECM830 electroporator (BTX, San Diego, CA, USA) was used to deliver eight 50 ms electric pulses separated by 100 ms with voltage set at 30 V. If not specifically mentioned, eyes were enucleated 65-68 h after transfection and anterior segments were removed. Posterior eyecups were minced and homogenized in 100 ml of Reporter Lysis Buffer (Promega). Firefly and Renilla luciferase activities were measured using 40 ml of lysate and Dual-Luciferase Reporter Assay System (Promega). Statistical analysis was done using ANOVA and Tukey-Kramer test.
